NASACORT Drug Patent Profile

« Back to Dashboard

Which patents cover Nasacort, and what generic alternatives are available?

Nasacort is a drug marketed by Chattem Sanofi and Sanofi Aventis Us and is included in three NDAs.

The generic ingredient in NASACORT is triamcinolone acetonide. There is one drug master file entry for this compound. Eighty suppliers are listed for this compound. Additional details are available on the triamcinolone acetonide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Nasacort

A generic version of NASACORT was approved as triamcinolone acetonide by SUN PHARMA CANADA on October 1^st, 1986.

Summary for NASACORT

US Patents:	0
Applicants:	2
NDAs:	3
Raw Ingredient (Bulk) Api Vendors:	68
Clinical Trials:	8
Patent Applications:	4,812
What excipients (inactive ingredients) are in NASACORT?	NASACORT excipients list
DailyMed Link:	NASACORT at DailyMed

Recent Clinical Trials for NASACORT

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Gail Gauvreau	N/A
Stanford University	Phase 4
Sanofi	Phase 4

See all NASACORT clinical trials

US Patents and Regulatory Information for NASACORT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Chattem Sanofi	NASACORT	triamcinolone acetonide	AEROSOL, METERED;NASAL	019798-001	Jul 11, 1991		DISCN	No	No
Chattem Sanofi	NASACORT ALLERGY 24 HOUR	triamcinolone acetonide	SPRAY, METERED;NASAL	020468-002	Oct 11, 2013		OTC	Yes	Yes
Sanofi Aventis Us	NASACORT HFA	triamcinolone acetonide	SPRAY, METERED;NASAL	020784-001	Apr 7, 2004		DISCN	No	No

Expired US Patents for NASACORT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Chattem Sanofi	NASACORT	triamcinolone acetonide	AEROSOL, METERED;NASAL	019798-001	Jul 11, 1991	4,767,612

Nasacort Market Dynamics and Financial Trajectory: OTC Allergic Rhinitis Drug Analysis

Last updated: October 30, 2026

Nasacort is a mature over-the-counter nasal corticosteroid brand based on triamcinolone acetonide. Its U.S. prescription-to-OTC transition in 2013 expanded consumer access but removed most regulatory exclusivity. The brand now competes in a commoditized allergy market against Flonase, Rhinocort, store brands, and generic triamcinolone nasal sprays.

Nasacort has commercial value as a cash-generating consumer-healthcare brand, but Sanofi does not report product-level sales. Public financial statements disclose performance for broader consumer-healthcare portfolios rather than Nasacort individually. Its financial trajectory is therefore best assessed through category growth, brand positioning, pricing, distribution, and portfolio ownership rather than standalone revenue.

What is Nasacort and who owns the brand?

Nasacort is a nasal spray containing triamcinolone acetonide, a synthetic corticosteroid used to treat symptoms of seasonal and perennial allergic rhinitis. The product reduces nasal congestion, sneezing, runny nose, and nasal itching.

Item	Current position
Brand	Nasacort
Active ingredient	Triamcinolone acetonide
Drug class	Intranasal corticosteroid
Primary indication	Allergic rhinitis
U.S. regulatory status	OTC nasal spray
Original commercial sponsor	Rhone-Poulenc/Rorer and later Aventis/Sanofi
Current consumer-healthcare platform	Opella, the Sanofi consumer-healthcare business
Main dosage form	Metered-dose nasal spray
Primary competitors	Flonase, Rhinocort, generic fluticasone, generic budesonide, generic triamcinolone
Prescription-to-OTC switch	2013 in the United States

Sanofi moved its consumer-healthcare operations into the Opella platform. In October 2024, Sanofi announced an agreement to sell a controlling interest in Opella to Clayton, Dubilier & Rice while retaining a minority holding. The transaction changes the ownership structure around brands such as Nasacort but does not change the product’s FDA status or active ingredient.[1]

When did Nasacort lose prescription exclusivity?

Nasacort lost meaningful prescription-market exclusivity before its OTC launch. The product’s commercial position changed in two stages:

Period	Event	Commercial effect
1990s	Nasacort introduced as a prescription nasal corticosteroid	Marketed through the prescription channel
2000s	Generic triamcinolone nasal products entered the prescription market	Reduced prescription pricing power
2013	FDA approved Nasacort Allergy 24HR for nonprescription use	Expanded consumer access and retail distribution
2014 onward	Major pharmacy, grocery, mass-retail, and e-commerce distribution	Increased shelf competition and price comparison
Current market	Brand and private-label products compete on price, efficacy perception, packaging, and availability	Low regulatory barriers and limited exclusivity

The 2013 OTC switch was strategically important because it changed Nasacort from a prescription brand into a mass-market self-care product. The switch increased the addressable consumer base but also exposed the brand to direct comparison with other OTC nasal sprays.

FDA approved Nasacort Allergy 24HR for adults and children aged 2 years and older for treatment of allergy symptoms. The OTC label instructs users to administer the product once daily and states that maximum benefit may require regular use over several days.[2]

What is the Orange Book status of Nasacort?

Nasacort has limited relevance to the current Orange Book exclusivity system because the principal commercial product is an OTC drug rather than a newly protected prescription product.

The FDA Orange Book is primarily used to identify approved prescription drug products, therapeutic equivalence evaluations, and certain patent or exclusivity information. OTC products approved through an NDA can appear in FDA databases, but an OTC brand with an old active ingredient generally does not have the type of current market exclusivity associated with a newly approved prescription medicine.[3]

Key implications include:

• No meaningful new-drug exclusivity protects triamcinolone acetonide as an active ingredient.
• Generic and store-brand alternatives are available.
• The OTC label and brand identity may remain commercially useful even when the underlying drug is commoditized.
• Any surviving formulation, device, or manufacturing claims would need to be evaluated separately from active-ingredient protection.
• Trademark and trade-dress rights are more relevant to current brand defense than pharmaceutical composition patents.

What patents protect Nasacort?

The commercial patent estate for Nasacort is weak compared with newer prescription drugs and biologics. The active ingredient, triamcinolone acetonide, is an established corticosteroid. Core composition-of-matter protection is no longer a meaningful barrier to generic or private-label competition.

Potential intellectual-property categories include:

1. Nasal-spray formulations.
2. Metered-dose delivery systems.
3. Manufacturing processes.
4. Container-closure systems.
5. Labeling and method-of-use claims.
6. Brand trademarks and packaging design.

These rights do not necessarily create a current barrier to competition. A formulation patent may protect a particular composition but not prevent competitors from marketing a non-infringing triamcinolone nasal spray. Device claims may have limited value where alternative pumps and delivery systems are available.

No current, broadly blocking Nasacort patent estate is publicly identified as the primary driver of market access. The competitive position instead depends on regulatory approvals, retail placement, consumer recognition, and manufacturing economics.

Are Paragraph IV challenges relevant to Nasacort?

Paragraph IV litigation is not the central competitive mechanism for Nasacort’s OTC market. Paragraph IV certifications apply to abbreviated new drug applications that challenge listed patents for reference products. Nasacort’s mature active ingredient and OTC positioning reduce the probability that a new entrant would face a commercially significant patent challenge involving core product rights.

The more likely entry pathways are:

• Abbreviated or streamlined generic approval routes.
• OTC monograph or monograph-aligned products where applicable.
• Private-label licensing and contract manufacturing.
• Retailer-owned store brands.
• Authorized or semi-authorized brand-equivalent products.

Nasacort’s principal risk is therefore sustained substitution rather than a single patent-driven launch event.

How does Nasacort compare with Flonase and Rhinocort?

Nasacort competes in a large OTC intranasal corticosteroid category. Product choice is influenced by efficacy expectations, onset claims, age labeling, spray feel, price, brand awareness, and retailer promotion.

Brand	Active ingredient	Parent or major marketer	Competitive position
Nasacort Allergy 24HR	Triamcinolone acetonide	Opella/Sanofi consumer-healthcare platform	Established non-drowsy allergy brand with broad OTC distribution
Flonase	Fluticasone propionate or other fluticasone products	Haleon and other marketers depending on product	Leading brand recognition and strong retail presence
Rhinocort Allergy	Budesonide	Organon and other marketers depending on jurisdiction	Established steroid nasal spray with broad consumer awareness
Generic products	Triamcinolone, fluticasone, budesonide	Multiple manufacturers	Price-led competition and private-label substitution
Antihistamine sprays	Azelastine and others	Multiple companies	Alternative mechanism and rapid-symptom positioning

Flonase generally has stronger consumer recognition in the U.S. allergy category. Nasacort’s differentiation depends less on a unique pharmacological mechanism than on brand equity, pricing, packaging, availability, and retailer support.

Clinical comparisons among intranasal corticosteroids often show broadly similar class efficacy when used correctly. This reduces the ability of Nasacort to maintain a premium solely through therapeutic differentiation. Consumer marketing and product experience become more important.

What are the main market dynamics for Nasacort?

OTC conversion expanded volume but compressed pricing

The OTC switch increased the number of potential users by removing the need for a physician prescription. It also moved the product into a price-sensitive retail environment. Consumers can compare branded and generic products directly on the shelf or online.

This creates a trade-off:

• Higher unit volume and broader distribution.
• Lower average selling prices.
• More promotional discounting.
• Greater retailer bargaining power.
• Increased private-label substitution.

Allergy prevalence supports recurring demand

Allergic rhinitis is a recurring condition with seasonal peaks and substantial self-treatment. U.S. demand is strongest during spring and early summer, with additional demand in regions affected by year-round indoor allergens.

The category benefits from:

• High prevalence of allergic rhinitis.
• Repeat annual purchases.
• Consumer familiarity with self-care.
• Low treatment complexity.
• Broad retail availability.

Demand is also sensitive to pollen intensity, weather conditions, air quality, geographic exposure, and consumer confidence.

Retail distribution is a primary competitive asset

Nasacort’s commercial performance depends on placement in pharmacies, mass merchants, grocery chains, warehouse clubs, and online marketplaces. Retailers can shift shelf space toward:

• Higher-margin private-label products.
• Better-performing national brands.
• Larger package sizes.
• Seasonal promotions.
• Products with stronger digital search conversion.

The brand must maintain distribution and visibility despite the absence of significant pharmaceutical exclusivity.

E-commerce increases price transparency

Online channels make brand-to-generic substitution easier. Consumers can compare the price per spray, package size, active ingredient, ratings, and delivery time. This increases pressure on premium pricing but also allows established brands to reach consumers outside traditional retail shelves.

What is the financial trajectory of Nasacort?

Nasacort’s financial trajectory is mature rather than growth-stage. The brand likely generates recurring revenue with seasonal volatility, but its contribution is embedded in Sanofi’s and Opella’s broader consumer-healthcare reporting.

Sanofi historically reported consumer-healthcare results at portfolio or geographic level rather than disclosing Nasacort revenue separately. Public filings do not provide a reliable standalone Nasacort revenue series, operating margin, or unit-volume history.[4]

The economic profile is likely characterized by:

Financial driver	Effect on Nasacort
OTC category growth	Supports unit demand
Generic and private-label entry	Reduces price and market share
Brand recognition	Supports retention and premium pricing
Retail promotions	Increases volume but compresses net price
Manufacturing scale	Supports gross margin
Seasonal demand	Creates inventory and working-capital swings
E-commerce	Improves reach but increases price transparency
Advertising expenditure	Needed to defend share against Flonase and store brands
Opella ownership transition	May change portfolio priorities and capital allocation

Nasacort is more likely to be managed as a cash-generative maintenance brand than as an innovation-led growth asset. The financial upside comes from distribution expansion, international penetration, pack architecture, premium positioning, and manufacturing efficiency rather than new molecular indications.

What revenue exposure does Nasacort create for Sanofi and Opella?

Nasacort contributes to consumer-healthcare revenue exposure, but its individual contribution cannot be calculated from public company filings. The commercial exposure is indirect:

1. Seasonal allergy demand creates recurring sales.
2. Category competition limits price expansion.
3. OTC distribution reduces dependence on prescription reimbursement.
4. Retail concentration increases negotiation pressure.
5. Brand investment is required to defend share.
6. A mature product has lower clinical-development costs than a prescription pipeline asset.

For Sanofi, Nasacort is not comparable to a major prescription product such as Dupixent in revenue scale or growth potential. For Opella, however, a portfolio of recognizable self-care brands can support recurring revenue, retailer relationships, manufacturing utilization, and cross-market distribution.

What generic launch risks exist for Nasacort?

Generic launch risk is persistent and structural rather than event-driven. Competitors do not need to overcome a high-value patent barrier to market triamcinolone-based nasal products.

The main risks are:

• Lower-priced generic sprays.
• Retailer conversion to private-label products.
• Substitution by fluticasone and budesonide.
• Promotional competition during allergy season.
• Reduced shelf space.
• Online price comparison.
• Consumer migration to alternative delivery systems.
• Retailer preference for higher-margin products.

Nasacort can defend against these risks through brand advertising, packaging differentiation, reliable supply, broad age labeling, product quality, spray performance, and consumer trust. These defenses are commercial rather than exclusivity-based.

What manufacturing and intellectual-property barriers affect Nasacort?

Manufacturing barriers are moderate. Nasal sprays require controlled formulation, metered-dose pump performance, container-closure compatibility, microbiological quality, and consistent spray characteristics. These requirements create technical execution challenges but do not constitute a durable barrier comparable to biologic manufacturing.

The principal operational risks include:

• Pump and actuator supply.
• Suspension uniformity.
• Dose-content consistency.
• Container compatibility.
• Stability during storage and distribution.
• Seasonal production planning.
• Regulatory compliance across multiple markets.

Because the active ingredient is established and the dosage form is widely used, experienced generic and contract manufacturers can typically develop competing products without recreating every aspect of the branded product.

What is the FDA regulatory status of Nasacort?

Nasacort Allergy 24HR is an FDA-authorized OTC product for allergic rhinitis. The OTC label covers adults and children two years of age and older, subject to the product labeling and dosing instructions.[2]

The principal regulatory considerations are:

• OTC labeling compliance.
• Manufacturing under current good manufacturing practices.
• Product quality and dose uniformity.
• Advertising substantiation.
• Adverse-event monitoring.
• Packaging and child-safety requirements.
• Import and supply-chain oversight.

No biosimilar pathway applies. Nasacort is a small-molecule corticosteroid, not a biologic. Biosimilar risk is therefore zero in the technical regulatory sense. Competitive risk comes from generic small-molecule products and alternative OTC allergy therapies.

What patent litigation and settlement agreements affect Nasacort?

No major current patent litigation or settlement agreement is publicly recognized as a material determinant of Nasacort’s U.S. commercial outlook. The product’s competitive profile is driven by long-established generic availability and OTC market execution.

This distinguishes Nasacort from newer prescription products where patent litigation, Paragraph IV filings, launch-at-risk decisions, and settlement dates determine market entry. For Nasacort, litigation is less likely to produce a discrete loss-of-exclusivity event because the major exclusivity loss occurred years ago.

How strong is the Nasacort patent estate?

Nasacort’s patent estate is weak as a source of exclusion but useful as a limited defensive asset.

Patent-estate factor	Assessment
Active-ingredient protection	Exhausted
Core prescription exclusivity	Exhausted
OTC exclusivity	Limited and not a durable barrier
Formulation protection	Potentially narrow and product-specific
Device protection	Potentially narrow and design-around risk is high
Method-of-use protection	Limited for established allergy indications
Trademark protection	Commercially relevant
Manufacturing know-how	Relevant to quality, cost, and supply reliability
Overall exclusionary strength	Low
Commercial brand value	Moderate, subject to category competition

What are the most likely future scenarios for Nasacort?

Base case: stable mature-brand performance

Nasacort retains broad retail distribution and recurring seasonal demand. Revenue remains relatively stable in nominal terms, with volume growth offset by price pressure and promotions.

Downside case: private-label substitution

Retailers increase store-brand allocation, generic prices decline, and Nasacort loses shelf space. The brand remains available but generates lower net sales and margins.

Upside case: portfolio optimization

Opella improves international distribution, expands e-commerce, uses targeted seasonal advertising, and optimizes pack sizes. Revenue growth remains moderate because the category lacks strong exclusivity.

Strategic-ownership case

The Opella ownership transition leads to greater emphasis on margin improvement, SKU rationalization, supply-chain efficiency, and high-return marketing. Nasacort could benefit from stronger commercial discipline, but lower-priority markets or weaker SKUs could face rationalization.[1]

Key Takeaways

• Nasacort is a mature OTC triamcinolone acetonide nasal spray.
• The product’s 2013 OTC switch expanded access but placed it in a price-sensitive consumer market.
• Core active-ingredient and prescription exclusivity are exhausted.
• No current patent estate is likely to block generic or private-label competition.
• Paragraph IV litigation is not the primary market-entry risk.
• Flonase, Rhinocort, generic sprays, and store brands are the principal competitors.
• Sanofi does not publicly disclose standalone Nasacort revenue.
• The brand’s value comes from recognition, retail distribution, seasonal demand, and manufacturing scale.
• Nasacort has no biosimilar risk because it is a small-molecule drug.
• Future performance will depend on pricing, shelf placement, digital distribution, retailer relationships, and Opella portfolio strategy.

FAQs About Nasacort Market Exclusivity and Commercial Outlook

Is Nasacort still under patent protection?

No meaningful active-ingredient patent protection remains for Nasacort. Any surviving formulation or device rights would be narrow and product-specific.

Can generic triamcinolone nasal spray replace Nasacort?

Yes. Generic triamcinolone products can provide therapeutic substitution, subject to product approval, labeling, availability, and consumer or retailer preference.

Is Nasacort a biologic or biosimilar product?

No. Nasacort is a small-molecule corticosteroid nasal spray. Biosimilar competition does not apply.

Does Sanofi disclose Nasacort sales?

No. Public reporting generally aggregates consumer-healthcare revenue and does not provide a reliable standalone Nasacort revenue figure.

What is the largest commercial threat to Nasacort?

The largest threat is sustained substitution by lower-priced generic and private-label nasal corticosteroids, supported by aggressive retail pricing and strong competing brands.

References

1. Sanofi. (2024). Sanofi enters into an agreement with Clayton, Dubilier & Rice for a controlling stake in Opella. Sanofi press release.

2. U.S. Food and Drug Administration. (2013). FDA approves first over-the-counter nasal spray to treat allergies. FDA consumer health information.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.

4. Sanofi. (2023). 2023 Universal Registration Document and annual financial report. Sanofi.